Business context and reporting period
Unaudited Form 10-Q for the three months ended March 31, 2015. The filing is for LabStyle Innovations Corp., a mobile-health company developing and commercializing the Dario diabetes-management system; the request identifies Dariohealth Corp., so the issuer identity should be verified. Financial amounts below are in U.S. dollars thousands unless stated otherwise.
Key financial results and position
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $67 | $0 |
| Cost of revenue / gross loss | $297 / $(230) | $421 / $(421) |
| Gross margin | Negative; about (343%) | Not meaningful with no revenue |
| Operating expenses / operating loss | $1,547 / $(1,777) | $2,247 / $(2,668) |
| Net loss | $(1,638) | $(2,984) |
| Basic and diluted loss per share | $(0.08) | $(0.70) |
| Operating cash used | $(1,525) | $(2,337) |
| Investing cash used | $(29) | $(116) |
| Financing cash provided | $1,956 | $4,002 |
Cash and cash equivalents were $1,855 at quarter-end, versus $1,453 at December 31, 2014. Current assets were $2,449 and current liabilities $1,666. Total assets were $3,424. The balance sheet shows a $3,853 warrant liability and $2,655 of Series A convertible preferred shares; no conventional borrowing balance is separately presented. Stockholders’ deficiency was $4,750. The company reported 27.9 million common shares outstanding at March 31 and 30,108,131 as of May 12, 2015.
Material changes versus the prior period
- First reported product revenue: $67, from Dario meters and related disposables; Q1 2014 revenue was zero. Sales were still at an early commercialization stage.
- Net loss narrowed by $1,346 (45%), primarily reflecting lower operating costs and improved net financial results, including warrant revaluation.
- Operating expenses fell $700 overall: R&D declined 20% to $883, sales and marketing fell 12% to $252, and general and administrative expenses fell 52% to $412. Management attributed reductions to lower subcontractor and payroll costs, management changes, and reduced stock compensation; higher clinical-trial costs partly offset R&D savings.
- Cost of revenue included a $62 inventory write-down. The company cited lower production-line depreciation after ceasing operation of its former production line as a reason for lower cost of revenue year over year.
- Cash from financing was lower than a year earlier, but the company raised $1,956 net in a February–March 2015 private placement. It issued 11.3 million common shares and warrants; common shares outstanding rose materially.
Outlook, risks, contingencies, and unusual items
- Going concern: Management estimated available liquidity would fund planned activity only into August 2015, including anticipated sales proceeds. The filing says substantial doubt exists about the company’s ability to continue as a going concern and additional capital is needed; there is no assurance financing will be available on acceptable terms or at all.
- Business outlook: For the remainder of 2015, the company planned to expand Dario’s launch, ramp manufacturing, marketing and distribution, continue product development and patent work, and pursue regulatory clearance. Management hoped to receive U.S. FDA 510(k) clearance during 2015, following resubmission on March 24, 2015; this was not assured.
- Regulatory and commercial risks: U.S. clearance remained pending, sales were limited, and the company depended on successful commercialization, distribution partners, reimbursement access, manufacturing scale-up, and further funding. The filing also identifies intellectual-property, partner, and execution risks.
- UK distributor dispute: In April 2015 the subsidiary cancelled its exclusive UK distribution agreement. The distributor alleged breach and indicated it planned legal action; the company disputed the claim and alleged material breach and misrepresentation by the distributor.
- Subsequent financing-related events: In April 2015, 400,093 shares were issued to three directors in exchange for reduced or waived cash compensation. In May, the company arranged an exercise-and-replacement warrant transaction; by May 14, 1,651,362 warrants had been exercised for $396, with replacement warrants to be issued under the arrangement.
- Other unusual accounting: Warrant fair-value movements produced $150 of income in Q1 2015, reducing the reported net loss; the warrant liability was $3,853 at March 31. Revenue recognition for distributor sales was generally on receipt of payment, reflecting limited payment-history experience.
Important facts for investors to verify
- Confirm the filing’s issuer—LabStyle Innovations Corp.—matches the intended Dariohealth Corp. entity and security.
- Check subsequent cash, financing, warrant exercises, and the company’s actual liquidity runway relative to the August 2015 estimate.
- Verify FDA clearance status and whether the company achieved the planned commercial launch, sales, and manufacturing scale-up.
- Review the UK distributor dispute’s resolution, potential exposure, and any effect on distribution or revenue.
- Assess dilution and potential proceeds from outstanding warrants, including terms and the warrant liability’s valuation sensitivity.